Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lusefi OD Film Approved in Japan: Taisho
February 10, 2022
- Chugai Sees Huge Potential in Its RAS Inhibitor with 15% of All Cancers Targeted: Research Chief
February 9, 2022
- Astellas’ Pompe Gene Therapy Proves Safe in PI/II Interim Data
February 9, 2022
- Japan Ethical Drug Sales Up 3.9% in December: Crecon
February 9, 2022
- Sales Reps’ Detailing Activities Decrease MOM, YOY in December: Intage
February 9, 2022
- New Disease Target Picked in Sosei-Takeda Drug Discovery Pact
February 9, 2022
- Sumitomo Dainippon to Boost Infectious Disease R&D, Eyes AMR/Malaria
February 8, 2022
- Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
- Kyowa Kirin Nets 50%-Plus Sales from Overseas in 2021, Crysvita as Major Driver
February 8, 2022
- Cosentyx 75 mg Syringe Now Available in Japan: Novartis
February 8, 2022
- Kyoto Univ. Spinoff, CiRA, AZ to Develop Method to Produce iPSC-Derived Renal Tissues
February 8, 2022
- Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
- Meiji Unit Slapped with £4.62 Million Fine over Anti-Competitive Practices in UK
February 8, 2022
- Kyorin Holdings to Merge Pharma Subsidiary in April 2023
February 7, 2022
- Opdivo Tops Japan Sales Ranking in January: Encise
February 7, 2022
- Aculys Pharma Begins Japan PI for Narcolepsy Drug Candidate
February 7, 2022
- Fujifilm to Boot Up Corporate Venture Capital for Life Science
February 7, 2022
- Mochida Files Inhaled Treprostinil for PAH in Japan
February 7, 2022
- Pharma Industry Frets Cost and Deadline of MHLW-Ordered Carcinogen Risk Inspections
February 7, 2022
- Eisai Aims for US Accelerated OK for Lecanemab in 2022; Japan/EU Filing Planned by March 2023
February 4, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…